Future Research Priorities for Morbidity Control of Lymphedema

BACKGROUND: Innovation in the treatment of lower extremity lymphedema has received low priority from the governments and pharmaceutical industry. Advancing lymphedema is irreversible and initiates fibrosis in the dermis, reactive changes in the epidermis and subcutis. Most medical treatments offered...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Indian J Dermatol
Autori principali: Narahari, S R, Aggithaya, Madhur Guruprasad, Moffatt, Christine, Ryan, T J, Keeley, Vaughan, Vijaya, B, Rajendran, P, Karalam, S B, Rajagopala, S, Kumar, N K, Bose, K S, Sushma, K V
Natura: Artigo
Lingua:Inglês
Pubblicazione: Medknow Publications & Media Pvt Ltd 2017
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5286751/
https://ncbi.nlm.nih.gov/pubmed/28216723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0019-5154.198039
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi